Dermatology

When cells survive, we can protect against the effects of inflammation

Our anti-aging glycopeptide, AAGP®, works as a dual agent in a way that could protect and recover skin from ultraviolet (UV) radiation or harsh chemicals or assist in the treatment of atopic dermatitis and burn injuries. For the millions of individuals who suffer from skin conditions worldwide, AAGP® could have a role to play in helping prevent sun damage, inflammation, scarring, or signs of aging and more.

The impact of AAGP®

Chronic skin conditions can be both physically and mentally painful. In the United States, more than 85 million people are affected by skin conditions each year, according to the American Academy of Dermatology. AAGP® can recover skin cells after the damage is done, as demonstrated in a laboratory setting. As a result, this molecule has the potential to make treatments for skin conditions more accessible and affordable.

We’re researching two major ways that AAGP® can help: inflammation protection as well as UV-radiation and burn recovery.

Potential applications

  • Cosmetics
  • Lip balm
  • Eczema
  • Rosacea
  • Sun burn treatments
  • Diabetic ulcers

Inflammation protection

The most common dermatological issue is inflammation. This can cause chronic conditions like eczema or rosacea. Occasional rashes can also occur from exposures to natural or chemical agents and sensitivities.

Your skin is your largest organ. When it becomes inflamed, visible reactions can happen. Figuring out what’s wrong and getting your skin back to normal is hard enough without answering questions from family and strangers about what’s wrong with your skin.

We’re in the preclinical research stage of discovering AAGP®’s ability to protect skin from inflammation and are working hard to advance AAGP® to clinical skin trials.

UV radiation and burn recovery

Currently, we’re in the discovery phase to understand how AAGP® can help skin recover from UV radiation and burns. Ultraviolet light can damage proteins and DNA in skin cells. It can also produce inflammatory mediators that increase cell death or alter skin elasticity and color. In our research, we’ve learned that AAGP® could protect human adult skin fibroblasts against high intensity UVA and UVC wavelengths, which suggest that AAGP mechanisms of cell protection could both protect and renew healthy skin. We’ll soon be moving on to the proof of concept and into preclinical stages of research.

For investors

At ProtoKinetix, we calculate the market value of AAGP® in how well it can take care of patients. We want to help medical treatments become more successful in improving lives and helping cells survive. But we know that as an investor, you also want to know how our biotechnology can help you.

The 2025 market forecast for the dermatology industry is $183 billion. Investing in the future of dermatological medicine will help you and the millions of people around the world who are living with skin conditions live higher quality lives. The potential of our anti-aging glycopeptide is endless, and we’ve only seen the tip of the iceberg.

Research partners

Since 2002, AAGP® has gone through international laboratory testing conducted by some of the top researchers in the world. See their scientific contributions.

Invest with us

ProtoKinetix has patented an anti-aging glycopeptide with the power to change lives through cell survival. The potential is endless, and we’ve only seen the tip of the iceberg. Get invested.

Research findings

Find out what we’ve learned so far about the impact AAGP® could have in the field of dermatology.
Organ image An Investigation into the Ability of AAGP to Protect Against UVA and UVC Stimulated Cell Death in Hela Cells and Adult Primary Fibroblasts – Read the release
Connect With Protokinetix
Contact the team at ProtoKinetix to learn more about AAGP®’s potential for dermatology applications.